Publicacions en què col·labora amb PALOMA ARAGONCILLO BALLESTEROS (16)

2013

  1. Eplerenone enhances cardioprotective effects of standard heart failure therapy through matricellular proteins in hypertensive heart failure

    Journal of Hypertension, Vol. 31, Núm. 11, pp. 2309-2319

2010

  1. Rosuvastatin added to standard heart failure therapy improves cardiac remodelling in heart failure rats with preserved ejection fraction

    European Journal of Heart Failure, Vol. 12, Núm. 9, pp. 903-912

2009

  1. Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect

    British Journal of Pharmacology, Vol. 156, Núm. 8, pp. 1218-1227

2007

  1. Efecto de la atorvastatina sobre la expresión vascular de los PPAR en conejos dislipémicos

    Clínica e investigación en arteriosclerosis, Vol. 19, Núm. 4, pp. 166-173

  2. Efecto de la atorvastatina sobre la expresión vascular de los PPAR en conejos dislipémicos

    Clinica e Investigacion en Arteriosclerosis, Vol. 19, Núm. 4, pp. 166-173

  3. Interactions between aldosterone and connective tissue growth factor in vascular and renal damage in spontaneously hypertensive rats

    Journal of Hypertension, Vol. 25, Núm. 3, pp. 629-638

  4. Papel del factor de crecimiento de tejido conectivo en el daño vascular asociado a hipertensión en ratas. Interacción con la aldosterona

    Clínica e investigación en arteriosclerosis, Vol. 19, Núm. 5, pp. 232-239

2006

  1. Activation of peroxisome proliferator-activated receptor-α and -γ In auricular tissue from heart failure patients

    European Journal of Heart Failure, Vol. 8, Núm. 2, pp. 154-161

  2. Role of connective tissue growth factor in vascular and renal damage associated with hypertension in rats. Interactions with angiotensin II

    JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, Vol. 7, Núm. 4, pp. 192-200

2005

  1. Eplerenone reduces oxidative stress and enhances eNOS in SHR: Vascular functional and structural consequences

    Antioxidants and Redox Signaling, Vol. 7, Núm. 9-10, pp. 1294-1301

2003

  1. Comparison between the effects of mixed dyslipidaemia and hypercholesterolaemia on endothelial function, atherosclerotic lesions and fibrinolysis in rabbits

    Clinical Science, Vol. 104, Núm. 4, pp. 357-365

  2. Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibition on inflammatory markers in atherosclerotic rabbits

    Clinical Science, Vol. 105, Núm. 6, pp. 655-662

2001

  1. Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits

    Nephrology Dialysis Transplantation, Vol. 16, Núm. SUPPL. 1, pp. 40-44

2000

  1. Effect of atorvastatin on endothelium-dependent constrictor factors in dyslipidemic rabbits

    General Pharmacology: The Vascular System, Vol. 34, Núm. 4, pp. 263-272

  2. The protective role of atorvastatin on function, structure and ultrastructure in the aorta of dyslipidemic rabbits

    Virchows Archiv, Vol. 437, Núm. 5, pp. 545-554

1999

  1. Receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits

    Hypertension, Vol. 34, Núm. 4 II, pp. 969-975